Opportunity Information: Apply for PA 07 274
Apply for PA 07 274
- The National Institutes of Health in the education environment health income security and social services sector is offering a public funding opportunity titled "Understanding and Treating Ataxia Telangiectasia (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113 Environmental Health 93.172 Human Genome Research 93.396 Cancer Biology Research 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.865 Child Health and Human Development Extramural Research 93.866 Aging Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Jan 4, 2007.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- Eligible applicants include: Public and State controlled institutions of higher education City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Private institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Small businesses Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Independent school districts.
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith based or community based organizations can apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The "Understanding and Treating Ataxia Telangiectasia (R03)" funding opportunity (PA-07-274) is a National Institutes of Health (NIH) small grant program focused on advancing research on Ataxia Telangiectasia (A-T). It is sponsored by multiple NIH institutes including the National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of Environmental Health Sciences (NIEHS). The announcement is also supported in collaboration with key disease-focused partners, the Ataxia Telangiectasia Children's Project and the A-T Ease Foundation. The central goal is to move the field forward by funding basic, translational, and clinical studies that explain how A-T symptoms arise and progress, and by speeding the development and evaluation of potential therapeutic approaches. A major theme of the announcement is also building momentum in A-T research by encouraging interdisciplinary work and creating tools, methods, datasets, or other resources that make future studies easier and more impactful.
This opportunity uses the NIH R03 mechanism, which is designed for small, focused projects that can be completed relatively quickly and with limited resources. The R03 format is commonly used for pilot and feasibility studies, small self-contained research projects, secondary analyses of existing datasets, and the development of research methods or new research technologies. The structure is meant to help investigators generate early evidence, test a promising idea, or build a resource that can later justify larger-scale support. An important practical point is that the R03 is not renewable, so the program is oriented toward well-defined short-term deliverables rather than long, multi-phase efforts.
In terms of budget and timing, applicants may request up to $50,000 per year in direct costs for up to two years, for a maximum of $100,000 in direct costs over the full project period. The number of awards is not fixed and depends on the volume, scientific quality, and cost of applications received, along with NIH priorities and available funds. The announcement notes that award size and duration can vary by project, but they must remain within the R03 limits described above. There is no cost sharing or matching requirement, which means applicants are not required to provide non-federal funds to participate.
The scientific scope is intentionally broad within the A-T mission. Projects may range from fundamental studies that clarify disease mechanisms and symptom development, to translational efforts that bridge laboratory findings toward clinical application, to clinical studies that inform management or treatment strategies. The FOA also explicitly aims to stimulate the development of resources that support the broader A-T research community, which could include tools, methodologies, or technologies that address barriers in studying this rare and complex disorder. Another stated objective is to accelerate promising therapeutic research, meaning proposals that help identify, refine, or preliminarily test treatment concepts are aligned with the program's intent, as long as they fit the small, time-limited R03 structure.
Eligibility is expansive and includes many organization types. Eligible applicants include public and private institutions of higher education, nonprofits both with and without 501(c)(3) status, small businesses and other for-profit organizations, state and local governments, U.S. territories and possessions, Native American tribal governments and tribally designated organizations, regional organizations, and eligible federal agencies. The announcement also specifies that foreign (non-U.S.) entities are eligible to apply, and that faith-based or community-based organizations may apply as well. This broad eligibility is intended to attract strong ideas from academic laboratories, clinical and hospital settings, nonprofit research groups, and industry or technology developers who might contribute relevant tools or early therapeutic concepts.
Administratively, this is a discretionary grant program under NIH, categorized across several activity areas and CFDA numbers reflecting the multi-institute nature of the announcement, including neuroscience and neurological disorders, cancer biology, human genome research, environmental health, child health and development, and aging research. The FOA was originally posted January 4, 2007, with multiple receipt dates rather than a single deadline, and it was later archived on February 2, 2010. It also runs in parallel with two companion announcements of the same scientific scope but different grant sizes and purposes: an R01 (PA-07-272) for full-scale research projects and an R21 (PA-07-273) for exploratory/developmental work. In practice, that means applicants with ideas that are too large for an R03, or that need a different level of preliminary development, could consider those parallel mechanisms depending on the maturity and resource demands of the project.
FAQs: Understanding and Treating Ataxia Telangiectasia (R03) (PA-07-274)
What is the "Understanding and Treating Ataxia Telangiectasia (R03)" opportunity?
It is a National Institutes of Health (NIH) small grant funding opportunity focused on advancing research on Ataxia Telangiectasia (A-T). It is listed as PA-07-274 and uses the NIH R03 mechanism.
What is the main goal of this funding opportunity?
The central goal is to move A-T research forward by supporting basic, translational, and clinical studies that explain how A-T symptoms arise and progress, and by speeding the development and evaluation of potential therapeutic approaches. A key theme is also building momentum in the field by encouraging interdisciplinary work and developing resources that make future studies easier and more impactful.
Which NIH institutes sponsor this announcement?
The opportunity is sponsored by multiple NIH institutes: the National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of Environmental Health Sciences (NIEHS).
Are any non-NIH partners involved?
Yes. The announcement is supported in collaboration with the Ataxia Telangiectasia Children's Project and the A-T Ease Foundation.
What grant mechanism does this opportunity use?
This opportunity uses the NIH R03 mechanism, which is designed for small, focused projects that can be completed relatively quickly and with limited resources.
What types of projects are typically appropriate for an R03?
The R03 format is commonly used for pilot and feasibility studies, small self-contained research projects, secondary analyses of existing datasets, and the development of research methods or new research technologies. It is intended to generate early evidence, test a promising idea, or create a resource that can support later, larger-scale work.
Is the R03 renewable?
No. The R03 is not renewable, so projects should be structured around well-defined short-term deliverables rather than long, multi-phase efforts.
What is the maximum budget allowed under this R03?
Applicants may request up to $50,000 per year in direct costs for up to two years, for a maximum of $100,000 in direct costs over the full project period.
What is the maximum project period?
Up to two years.
Are award size and project duration fixed?
No. The announcement notes that award size and duration can vary by project, but they must remain within the R03 limits (up to $50,000 per year direct costs, up to two years).
How many awards will be made?
The number of awards is not fixed. It depends on the volume, scientific quality, and cost of applications received, along with NIH priorities and available funds.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement, meaning applicants are not required to provide non-federal funds to participate.
What scientific areas and project types are within scope?
The scientific scope is intentionally broad within the A-T mission. It includes fundamental studies clarifying disease mechanisms and symptom development, translational efforts bridging laboratory findings toward clinical application, and clinical studies that inform management or treatment strategies. The announcement also encourages projects that develop tools, methods, datasets, technologies, or other resources that address barriers in studying this rare and complex disorder.
Does the announcement encourage interdisciplinary work?
Yes. A major theme is building momentum in A-T research by encouraging interdisciplinary work and creating tools, methods, datasets, or other resources that make future studies easier and more impactful.
Are therapeutic-development projects encouraged?
Yes. Another stated objective is to accelerate promising therapeutic research. Proposals that help identify, refine, or preliminarily test treatment concepts are aligned with the program's intent, as long as they fit the small, time-limited R03 structure.
Who is eligible to apply?
Eligibility is expansive. Eligible applicants include public and private institutions of higher education; nonprofits with and without 501(c)(3) status; small businesses and other for-profit organizations; state and local governments; U.S. territories and possessions; Native American tribal governments and tribally designated organizations; regional organizations; and eligible federal agencies.
Are foreign (non-U.S.) organizations eligible?
Yes. The announcement specifies that foreign (non-U.S.) entities are eligible to apply.
Can faith-based or community-based organizations apply?
Yes. The announcement states that faith-based or community-based organizations may apply.
Is this considered a discretionary grant program?
Yes. Administratively, it is described as a discretionary grant program under NIH.
Is this opportunity connected to specific NIH activity areas or CFDA categories?
Yes. It is categorized across several activity areas and CFDA numbers reflecting the multi-institute nature of the announcement, including neuroscience and neurological disorders, cancer biology, human genome research, environmental health, child health and development, and aging research.
When was this funding opportunity posted, and what is its current status?
The FOA was originally posted on January 4, 2007, had multiple receipt dates rather than a single deadline, and was later archived on February 2, 2010.
Were there companion funding announcements related to this opportunity?
Yes. The announcement runs in parallel with two companion announcements of the same scientific scope but different mechanisms: an R01 (PA-07-272) for full-scale research projects and an R21 (PA-07-273) for exploratory/developmental work.
How should an applicant decide between the R03 and the companion R01 or R21 announcements?
Based on the information provided, the R03 is best suited for small, focused, time-limited projects with short-term deliverables and limited resources. Applicants with ideas that are too large for an R03, or that require a different level of development or scale, could consider the companion R01 (full-scale research) or R21 (exploratory/developmental) mechanisms.
Does the announcement emphasize creating shared research resources?
Yes. A stated aim is to stimulate development of resources that support the broader A-T research community, including tools, methodologies, technologies, datasets, or other resources that reduce barriers and improve future studies.
Does the program focus only on basic research?
No. The scope spans basic, translational, and clinical studies, as long as the work aligns with understanding A-T symptom development and progression and/or accelerating therapeutic development within the small R03 framework.
Browse more opportunities from the same category: Education Environment Health Income Security and Social Services
Next opportunity: Research On Ethical Issues In Human Subjects Research (R01)
Previous opportunity: Understanding and Treating Ataxia Telangiectasia (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 07 274
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 07 274) also looked into and applied for these:
| Funding Opportunity |
|---|
| Bioengineering Research Grants (BRG)(R01) Apply for PA 07 279 Funding Number: PA 07 279 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Novel Approaches to Enhance Animal Stem Cell Research (R01) Apply for PA 07 303 Funding Number: PA 07 303 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Novel Approaches to Enhance Animal Stem Cell Research (R21) Apply for PA 07 304 Funding Number: PA 07 304 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Bioengineering Research Partnerships (BRP)R01 Apply for PAR 07 352 Funding Number: PAR 07 352 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $2,000,000 |
| Behavioral and Social Science Research on Understanding and Reducing Health Disparities (R21) Apply for PAR 07 380 Funding Number: PAR 07 380 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Advancing Novel Science in Women s Health Research (ANSWHR) R21 Apply for PAS 07 381 Funding Number: PAS 07 381 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $2,000,000 |
| Advancing Novel Science in Women s Health Research (ANSWHR) (R03) Apply for PAS 07 382 Funding Number: PAS 07 382 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Understanding and Treating Generalized and Focal Dystonias (R01) Apply for PA 07 397 Funding Number: PA 07 397 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Understanding and Treating Generalized and Focal Dystonias (R21) Apply for PA 07 398 Funding Number: PA 07 398 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Developmental Pharmacology (R01) Apply for PAR 07 416 Funding Number: PAR 07 416 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Neuroimaging Informatics Software Enhancement for Improved Interoperability and Dissemination (R03) Apply for PAR 07 417 Funding Number: PAR 07 417 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Data Ontologies for Biomedical Research (R01) Apply for PAR 07 425 Funding Number: PAR 07 425 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| ELSI Regular Research Program (R01) Apply for PA 08 012 Funding Number: PA 08 012 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| ELSI Small Research Grant Program (R03) Apply for PA 08 013 Funding Number: PA 08 013 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Community Participation in Research (R01) Apply for PA 08 074 Funding Number: PA 08 074 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Brain Disorders in the Developing World Research Across the Lifespan (R01) Apply for PAR 08 112 Funding Number: PAR 08 112 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Brain Disorders in the Developing World Research Across the Lifespan (R21) Apply for PAR 08 113 Funding Number: PAR 08 113 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Genetic Screens to Enhance Zebrafish Research (R01) Apply for PAR 08 138 Funding Number: PAR 08 138 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Methodology and Measurement in the Behavioral and Social Sciences (R01) Apply for PAR 08 212 Funding Number: PAR 08 212 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Methodology and Measurement in the Behavioral and Social Sciences (R21) Apply for PAR 08 213 Funding Number: PAR 08 213 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 07 274", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.